Clinical trials: Hematopoietic Neoplasms
Acute Myeloid Leukemia
Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT
The purposes of the study are to determine the maximum tolerated dose (MTD) and effectiveness of Artificial Antigen Presenting Cell (AAPC)-expanded donor T-cells administered as a single infusion after an allogeneic hematopoietic…
- Trial name
- NCT05015426
- Testing
- Gamma Delta T-Cell Infusion
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Breast Cancer, Colorectal Cancer
Prospective Collection of Surplus Surgical Tumor Tissues and Pre-surgical Blood Samples
The study is intended to collect specimens to support the application of genome analysis technologies, including large-scale genome sequencing.
- Conditions
- Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer
- Trial name
- GBCPRT0008 (NCT01792882)
- Where
- United States
- Sponsor
- Global BioClinical
Hematologic Malignancies
Phase II Trial of Pentostatin and Targeted Busulfan
The objective of this trial is to determine whether a regimen of pentostatin and busulfan (IV) can facilitate engraftment of human leukocyte antigen (HLA) partially compatible siblings and unrelated donor transplants by using…
- Trial name
- Pento & tBU (NCT00496340)
- Testing
- Pentostatin, Busulfan, Rituximab
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Hematological Malignancy
Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies
This is a single-arm, multicenter, exploratory clinical study to evaluate the safety and efficacy of the combination of etoposide, cytarabine and PEG-rhG-CSF (EAP regimen) on hematopoietic stem cell mobilization in poor…
- Trial name
- NCT05510089
- Testing
- Etoposide, Cytarabine, PEG-rhG-CSF
- Where
- 12 sites in China
- Volunteers
- 62 people
- Sponsor
- The Affiliated People's Hospital of Ningbo University
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Group Curriculum for Improving Survivorship Outcomes in Adolescent and Young Adult Cancer Survivors
This clinical trial studies the effectiveness of a group curriculum in improving survivorship outcomes in adolescent and young adult (AYA) cancer survivors.
- Trial name
- NCT05584449
- Testing
- Counseling, Discussion, Informational Intervention
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Mayo Clinic
Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
This phase II pediatric MATCH treatment trial studies how well selpercatinib works in treating patients with solid tumors that may have spread from where they first started to nearby tissue, lymph nodes, or distant parts of the…
- Conditions
- Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma
- Trial name
- NCT04320888
- Testing
- Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
- Where
- 174 sites in United States, Australia and 1 more
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Hematopoietic Stem Cell Transplantation, Breast Cancer
Treating Cancer-Related Fatigue Through Systematic Light Exposure
Cancer related fatigue (CRF) - a persistent sense of exhaustion related to cancer or cancer treatment - can severely interfere with activities of daily living, and has even been reported to be a factor in patient requests for…
- Conditions
- Hematopoietic Stem Cell Transplantation, Breast Cancer, Fatigue, Mild Cognitive Impairment
- Trial name
- NCT01873794
- Testing
- Bright white light, Dim red light
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Graft Vs Host Disease, Graft-versus-host-disease
TCRαβ/CD19 Depletion of Stem Cell Grafts for Transplant
The CliniMACS® device is FDA-approved only for one indication (CD34+ selection). Additional use of this device outside of this indication requires the use of feasibility studies.
- Conditions
- Graft Vs Host Disease, Graft-versus-host-disease, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
- Trial name
- NCT05968170
- Testing
- CliniMACS® device
- Sponsor
- Neena Kapoor, M.D.
Lymphoma, Non-Hodgkin, Hodgkin Disease
Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT)
For patients with lymphoma that recurs after chemotherapy, bone marrow transplantation using cells from a healthy donor represents potentially curative treatment.
- Trial name
- NCT01745354
- Testing
- SD-101, Local Radiation
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Robert Lowsky
Haemato-lymphoid Malignancies or Syndromes in Whom Allogeneic Stem Cell Transplantation is Warranted
Allogeneic Hematopoietic Stem Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-thymocyte Globulin for Older Patients With Relapsed Lymphoid Malignancies
Recent advances in allogeneic hematopoietic cell transplantation (allo-SCT) have led to reduce intensity preparative regimens that are non-myeloablative and reduce the toxicities associated with the transplant.
- Trial name
- TLI-ATG (NCT01566656)
- Testing
- total lymphoid irradiation and anti-thymocyte globulin
- Where
- 4 sites in France
- Volunteers
- 15 people
- Sponsor
- Nantes University Hospital
Breast Cancer, Leukemia
Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Breast Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00237627
- Testing
- PS-341, Doxil, Velcade
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Acute Myeloid Leukemia, Myelodysplastic Syndromes
A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies
The purpose of this study is to examine if it is feasible to administer decitabine and filgrastim after allogenic hematopoietic stem cell transplant (HCT) in children and young adults with myelodysplastic syndrome, acute myeloid…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloid Malignancies, MDS
- Trial name
- MORE (NCT05796570)
- Testing
- Decitabine, Filgrastim
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Franziska Wachter
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Ann Arbor Stage I Lymphoma, Ann Arbor Stage II Lymphoma
- Trial name
- NCT05334069
- Testing
- Questionnaire Administration, Biospecimen Collection
- Where
- 751 sites in United States
- Volunteers
- 2,900 people, healthy volunteers welcome
- Sponsor
- Alliance for Clinical Trials in Oncology
Hematopoietic Stem Cell Transplantation, Bone Marrow Transplant
The Effects of Heart Rate Variability Biofeedback Training on Hematopoietic Cell Transplantation Patients
Patients undergoing hematopoietic stem cell transplantation (HCT) often continue to experience anxiety, depression, isolation, and other psychosocial distress due to the severe nature of the transplant experience.
- Conditions
- Hematopoietic Stem Cell Transplantation, Bone Marrow Transplant, Heart Rate Variability, Autonomic Nervous System
- Trial name
- NCT04275830
- Testing
- Baseline Surveys, Heart rate variability biofeedback, Heart rate variability waitlist and Digital storytelling Control intervention
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Arizona State University
Philadelphia Chromosome Positive Acute Lymphocytic Leukemia, Stem Cell Transplantation
TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
The purpose of this study is to evaluate the efficacy of tyrosine kinase inhibitor(TKI) therapy based on molecular monitoring of BCR/ABL levels in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)undergoing…
- Conditions
- Philadelphia Chromosome Positive Acute Lymphocytic Leukemia, Stem Cell Transplantation, Minimal Residual Disease
- Trial name
- NCT01883219
- Testing
- TKIs
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
This phase I/II trial studies the side effects and best dose of 211^astatine(At)-BC8-B10 before donor stem cell transplant in treating patients with high-risk acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
- Trial name
- NCT03128034
- Testing
- Cyclosporine, Fludarabine Phosphate, Mycophenolate Mofetil
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Fred Hutchinson Cancer Center
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Adult Acute Lymphoblastic Leukemia in Remission
Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
This randomized phase II trial studies how well vaccine therapy works in reducing the frequency of cytomegalovirus severe infections (events) in patients with hematologic malignancies undergoing donor stem cell transplant.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Hodgkin Lymphoma
- Trial name
- NCT02396134
- Testing
- CMVpp65-A*0201 peptide vaccine, Laboratory Biomarker Analysis
- Where
- 5 sites in United States
- Volunteers
- 61 people
- Sponsor
- City of Hope Medical Center
CML, ALL
Unrelated Stem Cell Transplantation for Adults With Hematopoietic Disorders
This study performs HLA matched stem cell transplantation from unrelated donors in adults who require stem cell transplantation but do not have a matched related donor available.
- Conditions
- CML, ALL, AML, Myelodysplasia
- Trial name
- NCT00511537
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Francisco
Childhood Cancer
Neutrophil Extracellular Traps Formation Post-hematopoietic Stem Cell Transplantation
Identifying the post-transplantation phase wherein neutrophils recover their ability to release NETs could shed new light on the mechanism responsible for the increased susceptibility to infection among these patients and aid in…
- Trial name
- NETs post HSCT (NCT01491230)
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
E Coli Infections, Allogenic Transplant Patients
Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant
This is a Phase 1b/2a study in allogenic hematopoietic stem cell transplant patients to investigate the safety, PK, PD and preliminary efficacy of multiple oral administrations of SNIPR001 when given concomitantly with SoC…
- Trial name
- NCT06938867
- Testing
- SNIPR001 consists of genetically modified bacteriophages specifically targeting Escherichia coli
- Where
- 10 sites in United States
- Volunteers
- 66 people
- Sponsor
- SNIPR Biome Aps.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.